[Prognostic value of preoperative serum high sensitivity C-reactive protein in patients with endometrial cancer].

OBJECTIVE: To evaluate whether high sensitivity C-reactive protein (hs-CRP) is a predictive factor in the patients with endometrial cancer.
METHODS: The investigators retrospectively analyzed the clinical records of 110 patient with endometrial carcinoma treated at our institution for their initial serum hs-CRP level at pre-operation. Pearson's chi-square was used to evaluate the association of the level of hs-CRP with variables associated with a poor prognosis. COX proportional hazard model was employed to perform univariate and multivariate analyses.
RESULTS: The median serum level of hs-CRP in the patients with endometrial cancer was 5.58 mg/L (range: 0.02 - 140.54 mg/L). The serum level of hs-CRP was significantly associated with advanced tumor stage (P < 0.01), lymph node involvement (P < 0.05) and patient age (P < 0.05). Tumor stage, lymph node involvement, histological grade, post-operative adjuvant therapy and the serum level of hs-CRP were correlated with the overall and disease-free survivals. Tumor stage and the serum level of hs-CRP were independent factors. The rank correlation analysis showed that there was a positive correlation between the serum levels of hs-CRP and CA125 (P < 0.01).
CONCLUSION: The serum level of hs-CRP may serve as a prognostic parameter in patients with endometrial cancer. Further studies are warranted to validate its value.